Key result
Combined hypercoagulability and impaired fibrinolysis increased the risk of major cardiovascular events over 4 years compared to normal parameters.
Why the study?
Although plaque rupture is common, catastrophic clinical events are not, leading researchers to hypothesize that hypercoagulability and impaired fibrinolysis influence coronary thrombosis risk and long-term prognosis in CAD.
Do hypercoagulability and impaired fibrinolysis increase the risk of MACE in CAD patients undergoing PCI?
Cohort (n=2,705)
Do hypercoagulability and impaired fibrinolysis increase the risk of MACE in CAD patients undergoing PCI?
Answers are grounded in this paper and cite their sources.
Hypercoagulability and impaired fibrinolysis, as measured by thromboelastography, are associated with an increased risk of AMI presentation and long-term MACE following PCI.
Introduction: Although a plaque damage such as rupture is quite commonly observed, catastrophic event with clinical symptoms is not common in real practice. Hypothesis: Hypercoagulability and impaired fibrinolysis can be associated with the risk of coronary thrombosis and long-term clinical prognosis in patients with coronary artery disease (CAD). Methods: CAD patients who underwent percutaneous coronary intervention (PCI) (n=2,705) were enrolled (presented with acute myocardial infarction [AMI], 47.8%). Global hemostatic properties were evaluated with thromboelastographic assay (TEG ® ) showing hypercoagulability (maximal amplitude [MA]: platelet-fibrin clot strength) and impaired fibrinolysis (LY 30 : percent lysis 30 minutes after maximal clot strength). Major adverse cardiovascular events (MACEs) were defined as a composite of cardiovascular death, myocardial infarction, or stroke. Results: Patients presented with AMI showed higher MA (66.5±7.8 vs. 65.3±7.2 mm, P<0.001) and lower LY 30 levels (1.0±2.5% vs. 1.2±2.2%, P=0.009) compared with non-AMI patients. Combined criteria of ‘MA≥68 mm’ and ‘LY 30 <0.2%’ increased the risk of AMI occurrence by 1.7-fold. During 4-year follow-up, MACE was associated with ‘MA≥68 mm’ (hazard ratio [HR] 1.447, 95% confidential interval [CI] 1.051-1.992, P=0.024) and ‘LY 30 <0.2%’ (HR 1.328, 95% CI 0.965-1.828, P=0.081), respectively. In multivariate analysis, patients with ‘MA≥68 mm’ and ‘LY 30 <0.2%’ showed an increased risk of MACE compared to those with ‘MA<68 mm’ and ‘LY 30 ≥0.2%’ (adjusted HR 1.863, 95% CI 1.191-2.913, P=0.006) (Figure 1). Subgroup analysis showed that this trend was consistent irrespective of baseline demographics and lesional characteristics. Conclusions: Hypercoagulability and impaired fibrinolysis were more frequently observed in AMI patients. In addition, these properties were significantly associated with post-PCI clinical prognosis.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2021) conducted a cohort in Coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) (n=2,705). Combined hypercoagulability (MA≥68 mm) and impaired fibrinolysis (LY30<0.2%) vs. MA<68 mm and LY30≥0.2% was evaluated on Major adverse cardiovascular events (MACEs) (composite of cardiovascular death, myocardial infarction, or stroke) (adjusted HR 1.863, 95% CI 1.191-2.913, p=0.006). Combined hypercoagulability and impaired fibrinolysis increased the risk of major cardiovascular events over 4 years compared to normal parameters.
Synapse has enriched 10 related papers. Consider them for comparative context: